Clinical rheumatology · 2025
Leucine-rich alpha-2-glycoprotein 1 (LRG1) decrement during biologics therapy and its correlation with disease features and treatment outcomes in rheumatoid arthritis patients.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Zou Liang, Fan Qiuyu, Liu Ya, He Hao, Jia Chao
Аннотация
OBJECTIVES: Leucine-rich alpha-2-glycoprotein 1 (LRG1) was previously reported to regulate inflammation and arthritis progression. This study aimed to investigate the correlation of serum LRG1 level with disease features and response to biologics in rheumatoid arthritis (RA) patients.
METHODS: Seventy-eight RA patients who underwent biologics treatment were analyzed. Serum LRG1 level was detected by enzyme-linked immunosorbent assay at baseline (before biologics were initiated) and at weeks 6 and 12. Treatment response, low disease activity (LDA), and remission were analyzed on the basis of disease activity score in 28 joints. Moreover, serum LRG1 level in another 20 health controls was also analyzed.
RESULTS: LRG1 was greater in RA patients than in health controls (46.3 versus 28.6 µg/mL, P < 0.001), with an area under the curve of 0.795 for differentiating them according to the receiver operator characteristic curve. By correlation analysis, LRG1 was correlated with a greater body mass index (P = 0.007) and C-reactive protein level (P = 0.013) in RA patients and tended to be associated with swollen joint count but was not statistically significant (P = 0.052). Furthermore, LRG1 decreased from baseline to week 12 after biologics treatment in RA patients (P < 0.001). However, baseline LRG1 was not correlated with treatment response (P = 0.987), LDA (P = 0.405), or remission (P = 0.763) in RA patients. A decrease in LRG1 at week 12 (P = 0.028) was related to response achievement, and a decrease in LRG1 at week 6 (P = 0.047) and week 12 (P = 0.019) was related to LDA achievement.
CONCLUSION: LRG1 may aid in RA disease supervision, but further validation is needed. Key Points • LRG1 level can distinguish RA patients from health controls with a high AUC at 0.795. • LRG1 level is correlated with higher BMI and CRP level, and tends to be related to elevated SJC in RA patients. • LRG1 level after treatment is correlated with clinical response and LDA to biologics in RA patients, while its level before treatment fails to do so. • Collectively, LRG1 level shows a potential to be a biomarker for RA disease supervision.
METHODS: Seventy-eight RA patients who underwent biologics treatment were analyzed. Serum LRG1 level was detected by enzyme-linked immunosorbent assay at baseline (before biologics were initiated) and at weeks 6 and 12. Treatment response, low disease activity (LDA), and remission were analyzed on the basis of disease activity score in 28 joints. Moreover, serum LRG1 level in another 20 health controls was also analyzed.
RESULTS: LRG1 was greater in RA patients than in health controls (46.3 versus 28.6 µg/mL, P < 0.001), with an area under the curve of 0.795 for differentiating them according to the receiver operator characteristic curve. By correlation analysis, LRG1 was correlated with a greater body mass index (P = 0.007) and C-reactive protein level (P = 0.013) in RA patients and tended to be associated with swollen joint count but was not statistically significant (P = 0.052). Furthermore, LRG1 decreased from baseline to week 12 after biologics treatment in RA patients (P < 0.001). However, baseline LRG1 was not correlated with treatment response (P = 0.987), LDA (P = 0.405), or remission (P = 0.763) in RA patients. A decrease in LRG1 at week 12 (P = 0.028) was related to response achievement, and a decrease in LRG1 at week 6 (P = 0.047) and week 12 (P = 0.019) was related to LDA achievement.
CONCLUSION: LRG1 may aid in RA disease supervision, but further validation is needed. Key Points • LRG1 level can distinguish RA patients from health controls with a high AUC at 0.795. • LRG1 level is correlated with higher BMI and CRP level, and tends to be related to elevated SJC in RA patients. • LRG1 level after treatment is correlated with clinical response and LDA to biologics in RA patients, while its level before treatment fails to do so. • Collectively, LRG1 level shows a potential to be a biomarker for RA disease supervision.